CagriSema (cagrilintide with semaglutide) — analytical characterisation
Chromatographic conditions, identity, related substances, presentation, reconstitution and in-use stability.
§6Analytical characterisation
§6.1Chromatographic conditions
- Column
- C18, 2.1 × 150 mm, 1.7 µm
- Mobile phase and gradient
- Gradient designed to resolve both actives with at least 2.0 resolution between the two main peaks
- Detection
- UV 214 nm
- Retention
- Two main peaks; semaglutide typically the later-eluting of the pair under the stated conditions
§6.2Identity by mass spectrometry
Two deconvoluted masses must be recovered, near 4113.6 and near 3751. A certificate reporting a single mass for a combination product is prima facie non-conformant.[3]
§6.3Related substances and degradation
Table 7. Related substances recorded for CagriSema (cagrilintide with semaglutide), with the process or storage route that generates each and its analytical signature.
| Related substance | Origin | Analytical signature |
|---|---|---|
| Incorrect content ratio | Blend or fill error | The critical quality attribute unique to this product; requires quantification of both actives against separate reference standards |
| Impurities of either component | See individual monographs | Must be attributed to the correct parent |
Degradation routes
- Aggregation of the amylin component is the dominant stability risk
- Cross-reaction between components has not been reported
§7Presentation, reconstitution and storage
§7.1Presentation and reconstitution
- Presentation
- Investigational co-formulated solution for injection
- Reconstitution
- Where research-supply material is offered as a lyophilised blend, the Institute notes that reconstitution cannot correct an incorrect blend ratio and that the ratio must be verified analytically.
- Storage, lyophilised
- 2–8 °C
- Storage, reconstituted
- 2–8 °C
- In-use period
- No published in-use data
The Institute treats content ratio as a critical field for this product and records a certificate without it as not verified.
§7.2In-use stability
Applicable standards: CEI-MS-01 · CEI-MS-02 · CEI-MS-03 · CEI-MS-04 · CEI-MS-05 · CEI-MS-06. The full series is at methodological standards.
Working calculators: reconstitution and insulin-unit conversion · purity against peptide content · certificate minimum-data checker.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.